South Korea-based LISCure Biosciences Inc has signed a know-how license and development collaboration agreement and stock purchase agreement with United States-based Mayo Clinic, to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH), it was reported on Monday.
Both parties previously entered into a research collaboration agreement in the first half of 2021 for NASH candidates.
According to the contract, LISCure will receive Mayo Clinic's know-how to set up a new drug development of NASH program. Under the agreement, Mayo Clinic will become a shareholder in LISCure. Both firms will pursue the common goal of maximising the value of LISCure's therapeutics in metabolic diseases by expanding research and development activities such as discovering new indications and additional value-added candidates.
LISCure aims to minimise trial and error in preparation for a phase two clinical trial of its NASH candidate in the United States in 2022 by collaborating with Mayo Clinic.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study